Atea Pharmaceuticals
AVIR
115 hedge funds and large institutions have $154M invested in Atea Pharmaceuticals in 2025 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 33 increasing their positions, 39 reducing their positions, and 6 closing their positions.
150% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 6
8% more funds holding
Funds holding: 106 → 115 (+9)
5.43% more ownership
Funds ownership: 61.57% → 67% (+5.4%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
15% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 39
19% less capital invested
Capital invested by funds: $190M → $154M (-$35.5M)
96% less call options, than puts
Call options by funds: $163K | Put options by funds: $3.67M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$1.07M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$989K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$696K |
| 4 |
D.E. Shaw & Co
New York
|
+$577K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$478K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Almitas Capital
Santa Monica,
California
|
-$1.6M |
| 2 |
BlackRock
New York
|
-$715K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$608K |
| 4 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$464K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$392K |
AVIR Hedge Fund Activity: Q3 2025 in Review
115 of the 7,641 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q3 2025, worth a combined $154M — down 19% from $190M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new AVIR positions and 6 closed out — a net gain of 9 holders — while 33 added to existing stakes and 39 trimmed.
The largest buyer was Millennium Management, adding an estimated $1.07M. The largest seller was Almitas Capital, exiting entirely with an estimated $1.6M sold.
- 115 institutional investors held Atea Pharmaceuticals (AVIR) as of Q3 2025, up from 106 in Q2 2025.
- Funds reported $154M of Atea Pharmaceuticals stock for Q3 2025, down 19% quarter-over-quarter.
- 15 funds opened new Atea Pharmaceuticals positions in Q3 2025 and 6 closed out, a net change of +9 holders.
- The largest Atea Pharmaceuticals buyer in Q3 2025 was Millennium Management, an estimated $1.07M added.
- The largest Atea Pharmaceuticals seller in Q3 2025 was Almitas Capital, an estimated $1.6M sold.
Based on aggregated 13F filings for Q3 2025.